nach oben

Erschienen in:

26.11.2021 | Original Article

Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis

verfasst von: Elisangela Gueiber Montes, Fabiana Postiglioni Mansani, Alceu de Oliveira Toledo Júnior, Marcelo Derbli Schafranski, Bruno Queiroz Zardo, Fábio André dos Santos, Sabrina Grassiolli, Lorena de Freitas Calixto, Rômulo Lopes da Costa, Felício de Freitas Netto, José Carlos Rebuglio Vellosa

Erschienen in: Inflammopharmacology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Rheumatoid arthritis is an inflammatory disease with joint manifestations. In the presence of extra-articular manifestations, the morbidity and severity of the disease increase. Glucocorticoid is used as a treatment and may result in side effects related to cardiovascular risk.

Methods

This was a cross-sectional study including 59 volunteers with rheumatoid arthritis receiving treatment at a hospital of Campos Gerais that aimed to establish the relation between cardiovascular risk, glucocorticoid treatment and myeloperoxidase in these patients. Subjects were divided into two groups: using (n = 39) and without glucocorticoids (n = 20). They underwent clinical evaluation, physical examination and blood samples were taken. Statistical analysis was performed using Student’s t test and Mann–Whitney test. Logistic regression was performed to assess the cardiovascular risk. The significance level was 5% (α = 0.05). Calculations were performed using the Statistical Package for the Social Science version 21.0.

Results

There has been a significant difference between groups in blood glucose values (p = 0.012), which can be explained by the different percentage of diabetic patients in the groups. When assessing cardiovascular risk using the predictors of glucocorticoid dose, time of glucocorticoid use, myeloperoxidase, and C-reactive protein together, these were responsible for significantly predicting this risk (p = 0.015).

Conclusion

A significant relation between the predictor myeloperoxidase alone was also demonstrated (p = 0.037), it may be an important predictor of cardiovascular risk among individuals with rheumatoid arthritis.

Graphical abstract

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://doi.org/10.1002/art.27584CrossRefPubMed

Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM (2013) Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res 56(2–3):267–286. https://doi.org/10.1007/s12026-013-8398-7CrossRefPubMed

Aviña-zubieta JA, Abrahamowicz M, de Vera MA, Choi HK, Sayre EC, Rahman MM, Sylvestre MP, Wynant W, Esdaile JM, Lacaille D (2013) Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (united Kingdom) 52(1):68–75. https://doi.org/10.1093/rheumatology/kes353CrossRef

Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1(6):338–347. https://doi.org/10.1016/S1568-9972(02)00100-3CrossRefPubMed

Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe HJ (2017) Cardiovascular comorbidity in inflammatory rheumatological conditions. Deutsches Arzteblatt Int 114(12):197–203. https://doi.org/10.3238/arztebl.2017.0197CrossRef

Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN (2011) Continuous monitoring of circadian glycemic patterns in patients receiving Prednisolone for COPD. J Clin Endocrinol Metabol 96(6):1789–1796. https://doi.org/10.1210/jc.2010-2729CrossRef

Cansu GB, Cansu DÜ, Taşkıran B, Bilge ŞY, Bilgin M, Korkmaz C (2019) What is the optimal time for measuring glucose concentration to detect steroid-induced hyperglycemia in patients with rheumatic diseases? Clin Biochem 67:33–39. https://doi.org/10.1016/j.clinbiochem.2019.03.012CrossRefPubMed

Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Investig 94(1):437–444. https://doi.org/10.1172/JCI117342CrossRefPubMedPubMedCentral

Davis JM, Kremers HM, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56(3):820–830. https://doi.org/10.1002/art.22418CrossRefPubMed

Den Uyl D, Van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JWJ, Hoes JN, Dijkmans BAC, Diamant M (2012) Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 64(3):639–646. https://doi.org/10.1002/art.33378CrossRef

Ferreira JF, Ahmed Mohamed AA, Emery P (2016) Glucocorticoids and rheumatoid arthritis. Rheum Dis Clin North Am 42(1):33–46. https://doi.org/10.1016/j.rdc.2015.08.006CrossRefPubMed

Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, D’Amelio R (2014) Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists. J Transl Med 12(1):1–10. https://doi.org/10.1186/1479-5876-12-77CrossRef

Gulliford MC, Charlton J, Latinovic R (2006) Risk of diabetes associated with prescribed glucocorticoids in a large population. Diab Care 29(12):2728–2729. https://doi.org/10.2337/dc06-1499CrossRef

Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB (2017) Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int 37(9):1551–1557. https://doi.org/10.1007/s00296-017-3726-1CrossRefPubMed

Khan NA, Lawyer G, McDonough S, Wang Q, Kassem NO, Kas-Petrus F, Ye D, Singh KP, Kassem NOF, Rahman I (2019) Systemic biomarkers of inflammation, oxidative stress and tissue injury and repair among waterpipe, cigarette and dual tobacco smokers. Tob Control 29(Suppl 2):102–109. https://doi.org/10.1136/tobaccocontrol-2019-054958CrossRef

Kwon S, Hermayer KL (2013) Glucocorticoid-induced hyperglycemia. Am J Med Sci 345(4):274–277. https://doi.org/10.1097/MAJ.0b013e31828a6a01CrossRefPubMed

Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH (2019) Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS ONE 14(1):1–10. https://doi.org/10.1371/journal.pone.0210459CrossRef

Malle E, Marsche G, Panzenboeck U, Sattler W (2006) Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 445(2):245–255. https://doi.org/10.1016/j.abb.2005.08.008CrossRefPubMed

McInnes IB, Schett G (2011) Mechanism of disease the pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205–2219CrossRef

Memon AA, Zarrouk M, Ågren-Witteschus S, Sundquist J, Gottsäter A, Sundquist K (2020) Identification of novel diagnostic and prognostic biomarkers for abdominal aortic aneurysm. Eur J Prev Cardiol 27(2):132–142. https://doi.org/10.1177/2047487319873062CrossRefPubMed

Meuwese MC, Stroes ESG, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJP, Khaw KT, Boekholdt SM (2007) Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals The EPIC-Norfolk Prospective Population Study. J Am College Cardiol 50(2):159–165. https://doi.org/10.1016/j.jacc.2007.03.033CrossRef

Mills E, Devendra S (2015) Steroid-induced hyperglycaemia in primary care. London J Prim Care 7(5):103–106. https://doi.org/10.1080/17571472.2015.1082344CrossRef

Negrei C, Bojinca V, Balanescu A, Bojinca M, Baconi D, Spandidos DA, Tsatsakis AM, Stan M (2016) Management of rheumatoid arthritis: impact and risks of various therapeutic approaches (Review). Exp Ther Med 11(4):1177–1183. https://doi.org/10.3892/etm.2016.3045CrossRefPubMedPubMedCentral

Nicholls SJ, Hazen SL (2005) Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25(6):1102–1111. https://doi.org/10.1161/01.ATV.0000163262.83456.6dCrossRefPubMed

Ogawa Y, Tomotsune K, Suda T (2005) Glucocorticoid-induced diabetes Nippon Rinsho. Jpn J Clin Med 63(Suppl 2):324–328

Patel R, Magomedova L, Tsai R, Angers S, Orellana A, Cummins CL (2017) Separating the anti-inflammatory and diabetogenic effects of glucocorticoids through LXRβ antagonism. Endocrinology 158(4):1034–1047. https://doi.org/10.1210/en.2017-00094CrossRefPubMed

Podrez EA, Schmitt D, Hoff HF, Hazen SL (1999) Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Investig 103(11):1547–1560. https://doi.org/10.1172/JCI5549CrossRefPubMedPubMedCentral

Pope JE, Nevskaya T, Barra L, Parraga G (2016) Carotid artery atherosclerosis in patients with active rheumatoid arthritis: predictors of plaque occurrence and progression over 24 weeks. Open Rheumatol J 10(1):49–59. https://doi.org/10.2174/1874312901610010049CrossRefPubMedPubMedCentral

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am College Cardiol 63(25):2889–2934. https://doi.org/10.1016/j.jacc.2013.11.002CrossRef

Verhoeven F, Prati C, Maguin-Gaté K, Wendling D, Demougeot C (2016) Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis. Arthritis Res Ther 18(1):258. https://doi.org/10.1186/s13075-016-1157-0CrossRefPubMedPubMedCentral

Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141(10):764. https://doi.org/10.7326/0003-4819-141-10-200411160-00007CrossRefPubMed

Titel: Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis
verfasst von: Elisangela Gueiber Montes
Fabiana Postiglioni Mansani
Alceu de Oliveira Toledo Júnior
Marcelo Derbli Schafranski
Bruno Queiroz Zardo
Fábio André dos Santos
Sabrina Grassiolli
Lorena de Freitas Calixto
Rômulo Lopes da Costa
Felício de Freitas Netto
José Carlos Rebuglio Vellosa
Publikationsdatum: 26.11.2021
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 6/2021
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-021-00892-x

Efficacy and safety between early use and late use of celecoxib in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study

Original Article

Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases

Zur Zeit gratis
COVID-19
Original Article

Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease

Review

Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus

Review

Deubiquitylating enzymes: potential target in autoimmune diseases

Review

Beneficial effects of secretome derived from mesenchymal stem cells with stigmasterol to negate IL-1β-induced inflammation in-vitro using rat chondrocytes—OA management

Original Article

Springer Medizin

Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis

Abstract

Background

Methods

Results

Conclusion

Graphical abstract

Weitere Artikel der Ausgabe 6/2021

Efficacy and safety between early use and late use of celecoxib in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study

Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases

Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease

Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus

Deubiquitylating enzymes: potential target in autoimmune diseases

Beneficial effects of secretome derived from mesenchymal stem cells with stigmasterol to negate IL-1β-induced inflammation in-vitro using rat chondrocytes—OA management

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Efficacy and safety between early use and late use of celecoxib in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study

Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases

Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease

Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus

Deubiquitylating enzymes: potential target in autoimmune diseases

Beneficial effects of secretome derived from mesenchymal stem cells with stigmasterol to negate IL-1β-induced inflammation in-vitro using rat chondrocytes—OA management